Back
 IJCM  Vol.8 No.6 , June 2017
Darwinian Selection in Prostate Cancer and Medical Treatment
Abstract: Organisms evolved into different species to adapt to the environment according to the laws of Darwinian evolution. In a single life, prostate cancer cells can also evolve into tumor stem cells to adapt to the microenvironment, such as different chemotherapeutic drugs. These cancer cells become an unrestricted growth group relatively independent of the individual. The present review attempts to establish evidence that prostate cancer cells may survive by hormonotherapy and chemotherapy by gene amplification, mutation, and alternative splicing. Simultaneously, novel treatment strategies have been cited and evaluated, avoiding the resistance mechanisms.
Cite this paper: Song, C. (2017) Darwinian Selection in Prostate Cancer and Medical Treatment. International Journal of Clinical Medicine, 8, 353-367. doi: 10.4236/ijcm.2017.86033.
References

[1]   Chan, S.C. and Dehm, S.M. (2014) Constitutive Activity of the Androgen Receptor. Advances in Pharmacology, 70, 327-366.

[2]   Dalal, K., Roshan-Moniri, M., Sharma, A., Li, H., Ban, F., et al. (2014) Selectively Targeting the DNA-Binding Domain of the Androgen Receptor as a Prospective Therapy for Prostate Cancer. Journal of Biological Chemistry, 289, 26417-26429.
https://doi.org/10.1074/jbc.M114.553818

[3]   Sartor, A.O., Tangen, C.M., Hussain, M.H., Eisenberger, M.A., Parab, M., et al. (2008) Antiandrogen Withdrawal in Castrate-Refractory Prostate Cancer: A Southwest Oncology Group Trial (SWOG 9426). Cancer, 112, 2393-2400.
https://doi.org/10.1002/cncr.23473

[4]   Schweizer, M.T. and Yu, E.Y. (2015) Persistent Androgen Receptor Addiction in Castration-Resistant Prostate Cancer. Journal of Hematology & Oncology, 8, 128.
https://doi.org/10.1186/s13045-015-0225-2

[5]   Azad, A.A., Volik, S.V., Wyatt, A.W., Haegert, A., Le Bihan, S., et al. (2015) Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA, Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clinical Cancer Research, 21, 2315-2324.
https://doi.org/10.1158/1078-0432.CCR-14-2666

[6]   Tamae, D., Mostaghel, E., Montgomery, B., Nelson, P.S., Balk, S.P., et al. (2015) The DHEA-Sulfate Depot Following P450c17 Inhibition Supports the Case for AKR1C3 Inhibition in High Risk Localized and Advanced Castration Resistant Prostate Cancer. Chemico-Biological Interactions, 234, 332-338.

[7]   Lu, C. and Luo, J. (2013) Decoding the Androgen Receptor Splice Variants. Translational Andrology and Urology, 2, 178-186.

[8]   Liu, X., Ledet, E., Li, D., Dotiwala, A., Steinberger, A., et al. (2016) A Whole Blood Assay for AR-V7 and ARv567es in Patients with Prostate Cancer. The Journal of Urology, 196, 1758-1763.
https://doi.org/10.1016/j.juro.2016.06.095

[9]   Onstenk, W., Sieuwerts, A.M., Kraan, J., Van, M., Nieuweboer, A.J., et al. (2015) Efficacy of Cabazitaxel in Castration-Resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells. European Urology, 68, 939-945.
https://doi.org/10.1016/j.eururo.2015.07.007

[10]   Liu, G., Sprenger, C., Sun, S., Epilepsia, K.S., Haugk, K., et al. (2013) AR Variant Arv567es Induces Carcinogenesis in a Novel Transgenic Mouse Model of Prostate Cancer. Neoplasia, 15, 1009-1017.
https://doi.org/10.1593/neo.13784

[11]   Mostaghel, E.A., Page, S.T., Lin, D.W., Fazli, L., Coleman, I.M., et al. (2007) Intraprostatic Androgens and Androgen-Regulated Gene Expression Persist after Testosterone Suppression, Therapeutic Implications for Castration-Resistant Prostate Cancer. Cancer Research, 67, 5033-5041.
https://doi.org/10.1158/0008-5472.CAN-06-3332

[12]   Liu, C., Lou, W., Zhu, Y., Yang, J.C., Nadiminty, N., et al. (2015) Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. Cancer Research, 75, 1413-1422.
https://doi.org/10.1158/0008-5472.CAN-14-3080

[13]   Tian, X., He, Y. and Zhou, J. (2015) Progress in Antiandrogen Design Targeting Hormone Binding Pocket to Circumvent Mutation Based Resistance. Frontiers in Pharmacology, 6, 57.

[14]   Munuganti, R.S., Hassona, M.D., Leblanc, E., Frewin, K., Singh, K., et al. (2014) Identification of a Potent Antiandrogen That Targets the BF3 Site of the Androgen Receptor and Inhibits Enzalutamide-Resistant Prostate Cancer. Chemistry & Biology, 21, 1476-1485.

[15]   Jehle, K., Cato, L., Neeb, A., Muhle-Goll, C., Jung, N., et al. (2014) Coregulator Control of Androgen Receptor Action by a Novel Nuclear Receptor-Binding Motif. Journal of Biological Chemistry, 289, 8839-8851.
https://doi.org/10.1074/jbc.M113.534859

[16]   Brand, L.J., Olson, M.E., Ravindranathan, P., Guo, H., Kempema, A.M., et al. (2015) EPI-001 Is a Selective Peroxisome Proliferator-Activated Receptor-Gamma Modulator with Inhibitory Effects on Androgen Receptor Expression and Activity in Prostate Cancer. Oncotarget, 6, 3811-3824.
https://doi.org/10.18632/oncotarget.2924

[17]   Antonarakis, E.S., Chandhasin, C., Osbourne, E., Luo, J., Sadar, M.D., et al. (2016) Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer. Oncologist, 21, 1427-1435.
https://doi.org/10.1634/theoncologist.2016-0161

[18]   Banuelos, C.A., Lal, A., Tien, A.H., Shah, N., Yang, Y.C., et al. (2014) Characterization of Niphatenones That Inhibit Androgen Receptor N-Terminal Domain. PLoS ONE, 9, e107991.
https://doi.org/10.1371/journal.pone.0107991

[19]   Kumar, B., Khaleghzadegan, S., Mears, B., Hatano, K., Kudrolli, T.A., et al. (2016) Identification of miR-30b-3p and miR-30d-5p as Direct Regulators of Androgen Receptor Signaling in Prostate Cancer by Complementary Functional microRNA Library Screening. Oncotarget, 7, 72593-72607.

[20]   Shi, X.B., Ma, A.H., Xue, L., Li, M., Nguyen, H.G., et al. (2015) miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src. Cancer Research, 75, 5309-5317.
https://doi.org/10.1158/0008-5472.CAN-14-0795

[21]   Yang, Y., Jia, D., Kim, H., Abd Elmageed, Z.Y., Datta, A., et al. (2016) Dysregulation of miR-212 Promotes Castration Resistance through hnRNPH1-Mediated Regulation of AR and AR-V7, Implications for Racial Disparity of Prostate Cancer. Clinical Cancer Research, 22, 1744-1756.
https://doi.org/10.1158/1078-0432.CCR-15-1606

[22]   Ho, T.T., Huang, J., Zhou, N., Zhang, Z., Koirala, P., et al. (2016) Regulation of PCGEM1 by p54/nrb in Prostate Cancer. Scientific Reports, 6, Article No. 34529.
https://doi.org/10.1038/srep34529

[23]   Tummala, R., Nadiminty, N., Lou, W., Evans, C.P. and Gao, A.C. (2016) Lin28 Induces Resistance to Anti-Androgens via Promotion of AR Splice Variant Generation. The Prostate, 76, 445-455.
https://doi.org/10.1002/pros.23134

[24]   Antonarakis, E.S., Lu, C., Luber, B., Wang, H., Chen, Y., et al. (2015) Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 1, 582-591.
https://doi.org/10.1001/jamaoncol.2015.1341

[25]   Li, H., Xie, N., Gleave, M.E. and Dong, X. (2015) Catalytic Inhibitors of DNA Topoisomerase II Suppress the Androgen Receptor Signaling and Prostate Cancer Progression. Oncotarget, 6, 20474-20484.
https://doi.org/10.18632/oncotarget.4105

[26]   Ishikura, N., Kawata, H., Nishimoto, A., Nakamura, R., Tsunenari, T., et al. (2015) CH5137291, an Androgen Receptor Nuclear Translocation-Inhibiting Compound, Inhibits the Growth of Castration-Resistant Prostate Cancer Cells. International Journal of Oncology, 46, 1560-1572.

[27]   Moilanen, A.M., Riikonen, R., Oksala, R., Ravanti, L., Aho, E., et al. (2015) Discovery of ODM-201, a New-Generation Androgen Receptor Inhibitor Targeting Resistance Mechanisms to Androgen Signaling-Directed Prostate Cancer Therapies. Scientific Reports, 5, Article No. 12007.
https://doi.org/10.1038/srep12007

[28]   Szafran, A.T., Stephan, C., Bolt, M., Mancini, M.G., Marcelli, M., et al. (2017) High-Content Screening Identifies Src Family Kinases as Potential Regulators of AR-V7 Expression and Androgen-Independent Cell Growth. The Prostate, 77, 82-93.
https://doi.org/10.1002/pros.23251

[29]   Sugawara, T., Lejeune, P., Köhr, S., Neuhaus, R., Faus, H., et al. (2016) BAY 1024767 Blocks Androgen Receptor Mutants Found in Castration-Resistant Prostate Cancer Patients. Oncotarget, 7, 6015-6028.

[30]   Yu, Z., Cai, C., Gao, S., Simon, N.I., Shen, H.C. and Balk, S.P. (2014) Galeterone Prevents Androgen Receptor Binding to Chromatin and Enhances Degradation of Mutant Androgen Receptor. Clinical Cancer Research, 20, 4075-4085.
https://doi.org/10.1158/1078-0432.CCR-14-0292

[31]   Liu, C., Lou, W., Zhu, Y., Nadiminty, N., Schwartz, C.T., et al. (2014) Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer. Clinical Cancer Research, 20, 3198-3210.
https://doi.org/10.1158/1078-0432.CCR-13-3296

[32]   Mbatia, H.W., Ramalingam, S., Ramamurthy, V.P., Martin, M.S., Kwegyir-Afful, A.K., et al. (2015) Novel C-4 Heteroaryl 13-cis-Retinamide Mnk/AR Degrading Agents Inhibit Cell Proliferationand Migration and Induce Apoptosis in Human Breast and Prostate Cancer Cells and Suppress Growth of MDA-MB-231 Human Breast and CWR22Rv1 Human Prostate Tumor Xenografts in Mice. Journal of Medicinal Chemistry, 58, 1900-1914.
https://doi.org/10.1021/jm501792c

[33]   Yamashita, S., Lai, K.P., Chuang, K.L., Xu, D., Miyamoto, H., et al. (2012) ASC-J9 Suppresses Castration-Resistant Prostate Cancer Growth through Degradation of Full-Length and Splice Variant Androgen Receptors. Neoplasia, 14, 74-83.
https://doi.org/10.1593/neo.111436

[34]   Robinson, D., Van Allen, E.M., Wu, Y.M., Schultz, N., Lonigro, R.J., et al. (2015) Integrative Clinical Genomics of Advanced Prostate Cancer. Cell, 161, 1215-1228.
https://doi.org/10.1016/j.cell.2015.05.001

[35]   Welsbie, D.S., Xu, J., Chen, Y., Borsu, L., Scher, H.I., et al. (2009) Histone Deacetylases Are Required for Androgen Receptor Function in Hormone-Sensitive and Castrate-Resistant Prostate Cancer. Cancer Research, 69, 958-966.
https://doi.org/10.1158/0008-5472.CAN-08-2216

[36]   Gordon, V., Bhadel, S., Wunderlich, W., Zhang, J., Ficarro, S.B., et al. (2010) CDK9 Regulates AR Promoter Selectivity and Cell Growth through Serine 81 Phosphorylation. Molecular Endocrinology, 24, 2267-2280.
https://doi.org/10.1210/me.2010-0238

[37]   Gioeli, D., Black, B.E., Gordon, V., Spencer, A., Kesler, C.T., et al. (2006) Stress Kinase Signaling Regulates Androgen Receptor Phosphorylation, Transcription, and Localization. Molecular Endocrinology, 20, 503-515.
https://doi.org/10.1210/me.2005-0351

[38]   Karaca, M., Liu, Y., Zhang, Z., De Silva, D., Parker, J.S., et al. (2015) Mutation of Androgen Receptor N-Terminal Phosphorylation Site Tyr-267 Leads to Inhibition of Nuclear Translocation and DNA Binding. PLoS ONE, 10, e0126270.
https://doi.org/10.1371/journal.pone.0126270

[39]   Chen, S., Kesler, C.T., Paschal, B.M. and Balk, S.P. (2009) Androgen Receptor Phosphorylation and Activity Are Regulated by an Association with Protein Phosphatase 1. Journal of Biological Chemistry, 284, 25576-25584.
https://doi.org/10.1074/jbc.M109.043133

[40]   He, B., Lanz, R.B., Fiskus, W., Geng, C., Yi, P., et al. (2014) GATA2 Facilitates Steroid Receptor Coactivator Recruitment to the Androgen Receptor Complex. Proceedings of the National Academy of Sciences of the United States of America, 11, 18261-18266.
https://doi.org/10.1073/pnas.1421415111

[41]   Zhang, Z., Zhou, N., Huang, J., Ho, T.T., Zhu, Z., et al. (2016) Regulation of Androgen Receptor Splice Variant AR3 by PCGEM1. Oncotarget, 7, 15481-15491.

[42]   Faivre, E.J., Wilcox, D., Lin, X., Hessler, P., Torrent, M., et al. (2017) Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075. Molecular Cancer Research, 15, 35-44.
https://doi.org/10.1158/1541-7786.MCR-16-0221

[43]   Buchanan, G., Yang, M., Harris, J.M., Nahm, H.S., Han, G., et al. (2001) Mutations at the Boundary of the Hinge and Ligand Binding Domain of the Androgen Receptor Confer Increased Transactivation Function. Molecular Endocrinology, 15, 46-56. https://doi.org/10.1210/mend.15.1.0581

[44]   Brooke, G.N., Parker, M.G. and Bevan, C.L. (2008) Mechanisms of Androgen Receptor Activation in Advanced Prostate Cancer, Differential Co-Activator Recruitment and Gene Expression. Oncogene, 27, 2941-2950.
https://doi.org/10.1038/sj.onc.1210955

[45]   Lorente, D., Mateo, J., Zafeiriou, Z., Smith, A.D., Sandhu, S., et al. (2015) Switching and Withdrawing Hormonal Agents for Castration-Resistant Prostate Cancer. Nature Reviews Urology, 12, 37-47.
https://doi.org/10.1038/nrurol.2014.345

[46]   Malik, R., Khan, A.P., Asangani, I.A., Cieslik, M., Prensner, J.R., et al. (2015) Targeting the MLL Complex in Castration-Resistant Prostate Cancer. Nature Medicine, 21, 344-352.
https://doi.org/10.1038/nm.3830

[47]   Evaul, K., Li, R., Papari-Zareei, M., Auchus, R.J. and Sharifi, N. (2010) 3beta-Hydroxysteroid Dehydrogenase Is a Possible Pharmacological Target in the Treatment of Castration-Resistant Prostate Cancer. Endocrinology, 151, 3514-3520.
https://doi.org/10.1210/en.2010-0138

[48]   Lallous, N., Volik, S.V., Awrey, S., Leblanc, E., Tse, R., et al. (2016) Functional Analysis of Androgen Receptor Mutations That Confer Anti-Androgen Resistance Identified in Circulating Cell-Free DNA from Prostate Cancer Patients. Genome Biology, 17, 10.
https://doi.org/10.1186/s13059-015-0864-1

[49]   Asangani, I.A., Dommeti, V.L., Wang, X., Malik, R., Cieslik, M., et al. (2014) Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer. Nature, 510, 278-282.
https://doi.org/10.1038/nature13229

[50]   Chen, G., Wang, X., Zhang, S., Lu, Y., Sun, Y., et al. (2005) Androgen Receptor Mutants Detected in Recurrent Prostate Cancer Exhibit Diverse Functional Characteristics. The Prostate, 63, 395-406.
https://doi.org/10.1002/pros.20191

[51]   Claessens, F., Helsen, C., Prekovic, S., Van den Broeck, T., Spans, L., et al. (2014) Emerging Mechanisms of Enzalutamide Resistance in Prostate Cancer. Nature Reviews Urology, 11, 712-716.
https://doi.org/10.1038/nrurol.2014.243

[52]   Gustafson, J.L., Neklesa, T.K., Cox, C.S., Roth, A.G., Buckley, D.L., et al. (2015) Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging. Angewandte Chemie International Edition, 54, 9659-9662.
https://doi.org/10.1002/anie.201503720

[53]   Wright, J.L., Kwon, E.M., Ostrander, E.A., Montgomery, R.B., Lin, D.W., et al. (2011) Expression of SLCO Transport Genes in Castration-Resistant Prostate Cancer and Impact of Genetic Variation in SLCO1B3 and SLCO2B1 on Prostate Cancer Outcomes. Cancer Epidemiology, Biomarkers & Prevention, 20, 619-627.
https://doi.org/10.1158/1055-9965.EPI-10-1023

[54]   Richards, J., Lim, A.C., Hay, C.W., Taylor, A.E., Wingate, A., et al. (2012) Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-Type and Mutant Androgen Receptor, Arationale for Increasing Abiraterone Exposure or Combining with MDV3100. Cancer Research, 72, 2176-2182.
https://doi.org/10.1158/0008-5472.CAN-11-3980

 
 
Top